➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,183,282

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,183,282 protect, and when does it expire?

Patent 7,183,282 protects CAPLYTA and is included in one NDA.

This patent has forty-eight patent family members in seventeen countries.

Summary for Patent: 7,183,282
Title:Substituted heterocycle fused .gamma.-carbolines
Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) ##STR00001## or pharmaceutically acceptable salt forms thereof, wherein R.sup.1, R.sup.5, R.sup.6a, R.sup.6b, R.sup.7, R.sup.8, R.sup.9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
Inventor(s): Robichaud; Albert J. (Ringoes, NJ), Lee; Taekyu (Doylestown, PA), Deng; Wei (Lexington, MA), Mitchell; Ian S. (Lafayette, CO), Yang; Michael G. (Narberth, PA), Haydar; Simon (Newtown, PA), Chen; Wenting (Langhorne, PA), McClung; Christopher D. (Chicago, IL), Calvello; Emilie J. (Baltimore, MD), Zawrotny; David M. (Ann Arbor, MI)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:11/375,125
Patent Claim Types:
see list of patent claims
Composition; Compound;

Recent additions to Drugs Protected by US Patent 7,183,282

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE 209500 Dec 20, 2019 RX Yes   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 7,183,282

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE;ORAL 209500-001 Dec 20, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.